Hematopoietic Stem Cell Transplant Survivors Study

Phase 1

Completed

• Conditions: Stem Cell Transplant
• Interventions: Other: Standard of Care - Observation Only

• Registration Number: NCT02652052
• Lead Sponsor: Mayo Clinic

Brief Summary

The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.

Detailed Description

Hematopoietic Stem Cell Transplant (HSCT) survivors are at an increased risk for premature aging. No one has evaluated the biologic markers of premature aging and senescence in HSCT survivors and their correlation with clinical outcomes, lifestyle, and nutrition. The investigators will evaluate age-related changes in HSCT survivors, with specified measures of premature aging, and employ therapeutic opportunities based on targeting senescent cells by conducting the first in-human pilot study of senolytic drugs (in HSCT survivors utilizing a combination of senolytics).

Study Timeline

• Study First Submitted: 2015-11-19
• Study First Submitted QC: 2016-01-07
• Study First Posted: 2016-01-11
• Study Start: 2016-03-01
• Primary Completion: 2023-05-23
• Study Completion: 2023-05-23
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-13
• Last Update Posted: 2025-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

• Allogeneic HSCT patients surviving ≥ 1 year post-HSCT
• Diagnosis of both malignant and non-malignant conditions as HSCT indications
• HSCT survivors receiving any type of conditioning chemo/radiotherapy for HSCT
• Ability to provide written and verbal informed consent
• Age ≥ 18 years
• Platelets > 50,000 per microliter
• Hemoglobin (HB) > 9/dL
• Absolute neutrophil count (ANC) > 1000 per microliter

Exclusion Criteria

• HSCT survivor with human immunodeficiency virus (HIV) infection
• HSCT survivor with active hepatitis B or C HSCT survivor on any TKI for either Philadelphia chromosome positive cancers or for graft versus host disease (GVHD) treatments or for any other indication (e.g., imatinib for gastrointestinal stromal tumor [GIST], sorafenib for FLT3+ acute myeloid leukemia [AML] etc)
• HSCT survivor with any post-transplant maintenance chemotherapy
• Post-(allogeneic) transplant relapse of cancer
• Active progressive CHRONIC chronic or overlap GVHD (per the National Institute of Health [NIH] chronic GVHD criteria)
• Presence of uncontrolled psychiatric disorder
• Patient unable to give informed consent
• Extremely poor overall prognosis (<6 months as deemed by the primary transplant physician)
• HSCT survivors with confirmed drug addiction
• HSCT survivors with active coronary artery disease (CAD) [including angina] or active congestive heart failure (CHF)
• International HSCT survivors in whom loss to follow-up would be a concern as deemed by primary transplant physician
• Known hypersensitivity or allergy to dasatinib, or quercetin
• Presence of uncontrolled lupus
• Presence of uncontrolled pleural/pericardial effusions or ascites
• Presence of active new cancer (solid or hematologic) except non-melanoma skin cancers
• Presence of progeroid syndromes in family
• Invasive fungal or viral infection not responding to appropriate antifungal or antiviral therapies.
• Creatinine clearance < 60 mL/min/1.73 m2 based on the Cockcroft-Gault
• Inability to tolerate oral medications
• Presence or history of significant liver disease with total bilirubin and/or alkaline phosphatase (ALP) > 2 x upper limit normal (unless deemed to be due to Gilbert's syndrome) or as per clinical judgement
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN) or as per clinical judgement
• Active progressive ACUTE graft-versus-host disease
• Active progressive OVERLAP graft-versus-host disease
• Patients taking medications that are sensitive substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4(e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from infectious disease perspective, then they will be allowed only if the levels are therapeutic. Levels will be checked at baseline and also at day +4 post intervention
• Patients taking H2-antagonists or proton pump inhibitors
• Patients on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors etc)
• On antiplatelet agents (e.g. full dose aspirin, clopidogrel etc.). Baby aspirin if absolutely necessary from cardiac perspective will be allowed.
• On any quinolone antibiotic therapy for treatment or for prevention of infections.
• Corrected QT (QTc) > 450 msec. Common drugs that are well known in prolonging QTc include azithromycin, citalopram, escitalopram, fluconazole, and pentamidine. Baselines electrocardiogram (EKG) will be obtained in each patient and if QTc > 450 msec, then they will be excluded from the trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 1: Observational	Standard of Care - Observation Only	Standard of Care - Observation Only

Primary Outcome Measures

Name	Time	Method
Frailty	Up to 180 days	Evaluate the association of frailty with measures of senescence in HSCT survivors - level of frailty as assessed by FRIED

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States